Increased chances for early detection of Alzheimer's disease

September 22, 2015, Lund University

A method for detecting early signs of Alzheimer's disease using amyloid PET imaging works as well as the previously used cerebrospinal fluid sample method. This is the conclusion of a new Lund University study—the most thorough and extensive undertaken in the field so far.

The most commonly used tools for investigating early signs of Alzheimer's disease in Swedish public healthcare are various cognitive memory tests and computed tomography. For several years it has also been possible to carry out an analysis of a cerebrospinal which increases the chances of early detection. So far, however, only patients in memory clinics have been offered the test.

Recently, a method known as amyloid PET was approved for clinical use in Sweden. A special substance which binds to a protein in the brain, β-amyloid, is administered to the patient. This amyloid is a marker for Alzheimer's changes, which are then mapped with PET imaging.

Opinions have long been divided as to whether cerebrospinal fluid samples or PET imaging are the best tools for detecting early-stage Alzheimer's disease.

"In the study, both the cerebrospinal fluid sample and the amyloid PET scans were able to identify approximately 90 per cent of the patients who would be diagnosed with Alzheimer's later on. Our conclusion is therefore that the two methods work equally well to achieve this aim. One can thus choose the method on the basis of cost, expertise or patient preference", says Sebastian Palmqvist, MD, PhD, at Lund University.

Both methods are also good at identifying which individuals are healthy and unlikely to develop Alzheimer's disease within the next ten years. However, when the diagnosis is reached without reference to a cerebrospinal fluid sample or amyloid PET imaging, its accuracy can drop to 60–70 per cent.

Late detection of Alzheimer's disease is not only a problem for today's healthcare, but also for the development of future treatments.

"Previous drug trials to evaluate new treatments for the presence of amyloid in Alzheimer's cases failed, partly because treatment began too late in the course of the disease. With two accurate tools for early diagnosis, we can identify suitable participants at an early stage of Alzheimer's disease. This will considerably increase the chances of being able to prove a positive effect for new drugs", concludes Oskar Hansson, associate professor and neurologist at Lund University.

The research data originates from the Swedish BioFINDER study. 122 healthy elderly participants and 34 patients with who developed Alzheimer's within three years were investigated in the article. The study was then repeated in an American population group of 210 individuals. The new findings are presented in the American journal Neurology.

Explore further: Midlife changes in Alzheimer's biomarkers may predict dementia

More information: "Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease." Neurology.

Related Stories

Midlife changes in Alzheimer's biomarkers may predict dementia

July 6, 2015
Studying brain scans and cerebrospinal fluid of healthy adults, scientists have shown that changes in key biomarkers of Alzheimer's disease during midlife may help identify those who will develop dementia years later, according ...

Amyloid pet may lead to better treatment for Alzheimer's patients

June 8, 2015
New research presented during the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrates that amyloid positron emission tomography (amyloid PET) scans of the brain provide clearer ...

Down syndrome research untangles therapeutic possibilities for Alzheimer's

September 17, 2015
More than five million Americans are living with Alzheimer's disease (AD). Of them, 400,000 also have Down syndrome. Both groups have similar looking brains with higher levels of the protein beta amyloid. In fact, patients ...

Study shows feasibility of blood-based test for diagnosing Alzheimer's Disease

March 11, 2015
UCLA researchers have provided the first evidence that a simple blood test could be developed to confirm the presence of beta amyloid proteins in the brain, which is a hallmark of Alzheimer's disease.

A new test might facilitate diagnosis and drug development for Alzheimer's disease

March 23, 2012
An international team of researchers have developed a new method for measurement of aggregated beta-amyloid – a protein complex believed to cause major nerve cell damage and dysfunction in Alzheimer's disease. The new ...

Accuracy of dementia brain imaging must improve

September 1, 2015
MRI scans and other tools to detect and diagnose dementia are helpful but not definitive - according to new research from the University of East Anglia.

Recommended for you

New discoveries predict ability to forecast dementia from single molecule

December 11, 2018
Scientists who recently identified the molecular start of Alzheimer's disease have used that finding to determine that it should be possible to forecast which type of dementia will develop over time—a form of personalized ...

Researchers classify Alzheimer's patients in six subgroups

December 5, 2018
Researchers studying Alzheimer's disease have created an approach to classify patients with Alzheimer's disease, a finding that may open the door for personalized treatments.

Neuroscientists pinpoint genes tied to dementia

December 3, 2018
A UCLA-led research team has identified genetic processes involved in the neurodegeneration that occurs in dementia—an important step on the path toward developing therapies that could slow or halt the course of the disease. ...

Detecting signs of neurodegeneration earlier and more accurately

November 30, 2018
Signs of neurodegenerative diseases, appearing years before the emergence of clinical manifestations, can be detected during the examination of medical samples by means of fluorescence microscopy by using new sensitive and ...

Never-before-seen DNA recombination in the brain linked to Alzheimer's disease

November 21, 2018
Scientists from Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified gene recombination in neurons that produces thousands of new gene variants within Alzheimer's disease brains. The study, published today ...

New information on the pathological mechanisms of Alzheimer's disease

November 21, 2018
Researchers at the University of Helsinki have discovered a mechanism by which harmful tau protein aggregates are transmitted between neurons. Alongside amyloid plaques, tau aggregates in the brain are a significant factor ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.